Corporate health benefit expenditures have breached the $18,000 threshold this year, forcing major businesses to contend with mounting pressures led by a dramatic surge in prescription drug expenditures, according to insights released by benefits consultancy Marsh.

The 2026 National Survey Findings

Data compiled in the 2026 National Survey of Employer-Sponsored Health Plans indicates that the cumulative cost of corporate-backed health coverage reached $18,777 for every worker, marking a notable 7.3% jump throughout 2026. This upward trajectory outpaces general inflation by more than double, yet remains conservative compared to forecasts anticipated by various advisory firms for the upcoming year.

Published during the critical open enrollment window—the yearly period wherein personnel select or update medical protections for the upcoming cycle—the research is derived from a poll of 2,000 organizations conducted from June through August by Marsh.

Health benefit cost growth at this level can put pressure on employers’ other budget priorities, like hiring and wage growth, says Simon Camaj, Leader for Marsh US Health and Benefits. That’s why employers are pulling all available levers to keep costs sustainable while maintaining this essential protection for employees and their families.

Mitigation Strategies and Employee Impact

Marsh noted that average per-employee expenditures would have comfortably surpassed $20,000 had participating organizations not actively restructured benefits. These adjustments included augmenting out-of-pocket burdens such as deductibles and copayments, alongside trimming coverage parameters for specific therapies, notably GLP-1 weight loss medications.

Consequently, participants enrolled in preferred provider organization (PPO) arrangements—the predominant coverage framework—experienced higher payroll deductions. Monthly individual contributions escalated from $191 in 2025 to $202 in 2026, while family coverage outlays climbed from $709 to $753 monthly.

The Complex Role of GLP-1 Medications

Expenditures for popular GLP-1 weight-loss pharmaceuticals, which Marsh estimates average roughly $1,000 monthly prior to manufacturer rebates, are increasingly being excluded by corporate sponsors. The consultancy highlighted that coverage provisions for these treatments contracted significantly in 2026, falling to 41% and 58% among surveyed entities as leadership sought aggressive cost-containment measures.

GLP-1s for weight loss are still very new, says Alysha Fluno, National Pharmacy Practice Leader for Marsh US Health and Benefits. Employers are seeking to provide a more holistic experience to help members manage the side effects of GLP-1s and, with or without medication, make the healthy lifestyle changes that will improve their weight loss outcomes.